- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Alkermes Plc (ALKS)
Alkermes Plc stock price live, this page displays NASDAQ ALKS stock exchange data. View the ALKS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Alkermes Plc real time stock price chart below.
What Is the Alkermes Plc Stock Price Today?
The Alkermes Plc stock price today is 27.00.
What Is the Stock Symbol for Alkermes Plc?
The stock symbol for Alkermes Plc is "ALKS."
What Stock Exchange Does Alkermes Plc Trade On?
Alkermes Plc is listed and trades on the NASDAQ stock exchange.
Is Alkermes Plc a Good Stock to Buy?
Determining whether Alkermes Plc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ALKS quote. (ISIN: IE00B56GVS15)
What Is the Alkermes Plc Stock Price Today?
The Alkermes Plc stock price today is 27.00.
What Is the Stock Symbol for Alkermes Plc?
The stock symbol for Alkermes Plc is "ALKS."
What Stock Exchange Does Alkermes Plc Trade On?
Alkermes Plc is listed and trades on the NASDAQ stock exchange.
Is Alkermes Plc a Good Stock to Buy?
Determining whether Alkermes Plc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ALKS quote. (ISIN: IE00B56GVS15)
27.00
-0.20(-0.74%)
Closed·
After Hours
27.000.00(0.00%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
26.98
27.52
52 wk Range
22.90
36.45
ALKS Scorecard
Full Analysis
Management has been aggressively buying back shares
Earnings results expected in 11 days
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
26.9827.52
52 wk Range
22.9036.45
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ALKS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
39.71
Upside
+47.09%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Holds more cash than debt on its balance sheet
Alkermes Plc Company Profile
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Alkermes Plc SWOT Analysis
Neuro-Innovation Surge | Alkermes' transformation into a high-growth neuro-innovator is reshaping its market position, driven by a robust product portfolio and promising pipeline |
Financial Resilience | Strong Q2 results and a solid cash position of $962.5 million provide Alkermes with flexibility for R&D investments and shareholder value creation |
LYBALVI's Momentum | Explore how LYBALVI's 52% year-over-year sales growth and increased prescriber breadth are bolstering Alkermes' commercial success in the CNS market |
Pipeline Potential | Delve into ALKS 2680's promising results in narcolepsy trials and its potential to position Alkermes as a leader in sleep disorder treatments |
Alkermes Plc Earnings Call Summary for Q4/2024
- Alkermes Q4 2024 EPS at $1.05, beating $0.75 forecast; revenue of $430M surpassed $380.75M estimate
- Stock rose 2.63% to $32.80 in premarket trading; company maintains strong financial health with 3.66 score
- 2024 total revenues exceeded $1.5B; proprietary product sales up 18% YoY, driven by LYVOLVY and VIVITROL
- Company ended year debt-free with $825M cash; projects 2025 revenues of $1.34B-$1.43B and EBITDA of $215M-$245M
- LYVOLVY expected to grow 25% in 2025; VIVITROL forecasted for mid-single-digit growth
Last Updated: 12-02-2025, 07:44 pm
Read Full TranscriptCompare ALKS to Peers and Sector
Metrics to compare | ALKS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALKSPeersSector | |
|---|---|---|---|---|
P/E Ratio | 12.0x | 0.0x | −0.5x | |
PEG Ratio | 3.45 | 0.00 | 0.00 | |
Price/Book | 3.0x | 0.0x | 2.6x | |
Price / LTM Sales | 2.9x | 0.0x | 2.9x | |
Upside (Analyst Target) | 44.4% | 0.0% | 57.8% | |
Fair Value Upside | Unlock | 0.0% | 10.2% | Unlock |
Analyst Ratings
9 Buy
6 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 39.71
(+47.09% Upside)
Earnings
Latest Release
Feb 12, 2025
EPS / Forecast
1.05 / 0.75
Revenue / Forecast
430.00M / 380.75M
FAQ
What Is the Alkermes Plc (ALKS) Stock Price Today?
The Alkermes Plc stock price today is 27.00.
What Stock Exchange Does Alkermes Plc Trade On?
Alkermes Plc is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Alkermes Plc?
The stock symbol for Alkermes Plc is "ALKS."
What Is the Alkermes Plc Market Cap?
As of today, Alkermes Plc market cap is 4.45B.
What is Alkermes Plc Earnings Per Share?
The Alkermes Plc EPS is 2.25.
What Is the Next Alkermes Plc Earnings Date?
Alkermes Plc will release its next earnings report on 30 Apr 2025.
From a Technical Analysis Perspective, Is ALKS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.